Private Equity Deal Spotlight | Weekly Update

Health care continues to drive private equity (“PE”) activity, creating opportunities for investors and traditional health care providers. Transactions in the health care space are especially complicated, layering health care regulatory and reimbursement considerations on top of a complex securities, antitrust, privacy and security framework.

Hall Render’s PE team of attorneys and advisors leverage the strength and depth of our bench to navigate and efficiently execute PE transactions. The summary below includes highlights of recent PE deals and legislative updates.

• Bain Capital has entered an agreement to acquire HealthEdge, a software-as-a-service platform connecting health plans, providers and patients with digital solutions in order to optimize health operations and improve outcomes. HealthEdge’s platform is used by over 115 health plans across the United States. Bain Capital is a Boston, Massachusetts-based global PE firm with $185 billion in assets under management.
• BayPine LP announced the acquisition of CenExel Clinical Research, a clinical trial site network specializing in complex therapeutics. CenExel facilitates key aspects of clinical development, including protocol creation, patient recruitment and engagement and clinical trial management and data collection. BayPine’s funding will be used to bolster CenExel’s data infrastructure and power AI-enabled tools to improve patient recruitment and site performance. BayPine is a PE firm based in Boston, Massachusetts, focused on technology industry investments.
• New Mountain Capital announced an investment in Thoughtful.ai. Thoughtful.ai hosts several revenue cycle management AI tools aimed at improving the performance of health care operations. The partnership is intended to improve efficiency and reliability while redefining operations within the health care industry. New Mountain Capital, headquartered in New York City, is a PE firm with over $55 billion in assets under management.
• Revelstoke Capital Partners made a significant investment in AOM Infusion. AOM provides intravenous immunoglobulin, biologics and other therapies to patients with chronic conditions, as well as services such as skilled infusion nursing administration, pharmacy, referral management and more. Revelstoke’s capital will be used to expand AOM’s therapeutic focus areas to ensure patients continue to receive high-quality infusion therapy. Revelstoke Capital Partners is a Denver, Colorado-based PE firm with a focus on health care investments.

For questions or additional information on private equity matters, please contact: